Lipid-lowering effects of gefarnate in statin-treated patients with residual hypertriglyceridemia:a randomized controlled study
Jing SHI1
Ming-Lu XU1
Mei-Jiao HE1
Wan-Lan BO2
Hai-Yu ZHANG1
Dang-Hui SUN1
Ding-Yu WANG1
Xiao-Yu WANG1
Qun SHAO3
Yu-Jiao PAN1
Yu ZHANG1
Chen-Guang DAI1
Jing-Ying WANG1
Lin-Wei ZHANG1
Guang-Zhong LIU4
Yue LI5
for the G-PROT Study Group
1.Department of Cardiology,the First Affiliated Hospital,Harbin Medical University,Harbin,China2.Department of Gastroenterology,the Fourth Affiliated Hospital,Harbin Medical University,Harbin,China3.Department of Cardio-logy,Harbin Medical University Cancer Hospital,Harbin,China4.Department of Cardiology,Shenzhen People's Hos-pital,Shenzhen,China5.Department of Cardiology,the First Affiliated Hospital,Harbin Medical University,Harbin,China;National Key Laboratory of Frigid Zone Cardiovascular Diseases,Harbin Medical University,Harbin,China;NHC Key Laboratory of Cell Transplantation,Key Laboratory of Cardiovascular Disease Acousto-Optic Electromagnetic Diagnosis and Treatment in Heilongjiang Province,Heilongjiang Province Clinical Medical Research Center for Hypertension,the First Affiliated Hospital,Harbin Medical University,Harbin,China;Institute of Metabolic Disease,Heilongjiang Academy of Medical Science,Harbin,China
摘要：BACKGROUND The prevention of coronary artery disease(CAD)faces dual challenges:the aspirin-induced gastrointestinal injury,and the residual cardiovascular risk after statin treatment.Geraniol acetate(Gefarnate)is an anti-ulcer drug.It was report-ed that geraniol might participate in lipid metabolism through a variety of pathways.The aim of this study was to assess the lipid-lowering effects of gefarnate in statin-treated CAD patients with residual hypertriglyceridemia.
METHODS In this prospective,open-label,randomized,controlled trial,69 statin-treated CAD patients with residual hypert-riglyceridemia were randomly assigned to gefarnate group and control group,received gefarnate(100 mg/3 times a day)comb-ined with statin and statin alone,respectively.At baseline and after one-month treatment,the levels of plasma triglyceride,high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)and total cholesterol were tested.
RESULTS After one-month gefarnate treatment,triglyceride level was significantly lowered from 2.64 mmol/L to 2.12 mmol/L(P=0.0018),LDL-C level lowered from 2.7 mmol/L to 2.37 mmol/L(P=0.0004),HDL-C level increased from 0.97 mmol/L to 1.17 mmol/L(P=0.0228).Based on statin therapy,gefarnate could significantly reduce the plasma triglyceride level(P=0.0148)and increase the plasma HDL-C level(P=0.0307).Although the LDL-C and total cholesterol levels tended to decrease,there was no st-atistically significant difference.
CONCLUSIONS The addition of gefarnate to statin reduced triglyceride level and increased HDL-C level to a significant ext-ent compared to statin alone in CAD patients with residual hypertriglyceridemia.This suggested that gefarnate might provide the dual benefits of preventing gastrointestinal injury and lipid lowering in CAD patients.
机标关键词：gefarnatestudypertwithcontrolledeffectslipid-loweringpatients
论文发表日期：2024-08-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：8( 791-798 )